KR101525631B1 - 개 흉선 간질 림포포이에틴 단백질 및 이의 용도 - Google Patents

개 흉선 간질 림포포이에틴 단백질 및 이의 용도 Download PDF

Info

Publication number
KR101525631B1
KR101525631B1 KR1020097014362A KR20097014362A KR101525631B1 KR 101525631 B1 KR101525631 B1 KR 101525631B1 KR 1020097014362 A KR1020097014362 A KR 1020097014362A KR 20097014362 A KR20097014362 A KR 20097014362A KR 101525631 B1 KR101525631 B1 KR 101525631B1
Authority
KR
South Korea
Prior art keywords
tslp
ala
protein
arg
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097014362A
Other languages
English (en)
Korean (ko)
Other versions
KR20090097921A (ko
Inventor
제아닌 디. 맷쏜
다니엘 엠. 고어만
왈 말레피트 르네 드
모하매드 에이. 모어시
Original Assignee
엠에스디 인터내셔널 홀딩즈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엠에스디 인터내셔널 홀딩즈 게엠베하 filed Critical 엠에스디 인터내셔널 홀딩즈 게엠베하
Publication of KR20090097921A publication Critical patent/KR20090097921A/ko
Application granted granted Critical
Publication of KR101525631B1 publication Critical patent/KR101525631B1/ko
Assigned to 인터벳 인터내셔널 비.브이. reassignment 인터벳 인터내셔널 비.브이. 권리의 전부이전등록 Assignors: 엠에스디 인터내셔널 홀딩즈 게엠베하
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43Sweetening agents, e.g. thaumatin, monellin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5418IL-7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/5418IL-7
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/20Dermatological disorders
    • G01N2800/202Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020097014362A 2006-12-14 2007-12-11 개 흉선 간질 림포포이에틴 단백질 및 이의 용도 Active KR101525631B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87513506P 2006-12-14 2006-12-14
US60/875,135 2006-12-14
PCT/US2007/025318 WO2008076255A2 (en) 2006-12-14 2007-12-11 Canine thymic stromal lymphopoietin protein and uses thereof

Publications (2)

Publication Number Publication Date
KR20090097921A KR20090097921A (ko) 2009-09-16
KR101525631B1 true KR101525631B1 (ko) 2015-06-04

Family

ID=39430681

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097014362A Active KR101525631B1 (ko) 2006-12-14 2007-12-11 개 흉선 간질 림포포이에틴 단백질 및 이의 용도

Country Status (18)

Country Link
US (3) US7718772B2 (https=)
EP (1) EP2104683B1 (https=)
JP (4) JP2010512744A (https=)
KR (1) KR101525631B1 (https=)
CN (2) CN101631800B (https=)
AU (1) AU2007334531B2 (https=)
BR (1) BRPI0720001A2 (https=)
CA (1) CA2671865C (https=)
CO (1) CO6210756A2 (https=)
ES (1) ES2582655T3 (https=)
IL (2) IL199170A (https=)
IN (1) IN2009CN03372A (https=)
MX (1) MX2009006470A (https=)
NZ (1) NZ578352A (https=)
RU (2) RU2457217C2 (https=)
UA (3) UA95329C2 (https=)
WO (1) WO2008076255A2 (https=)
ZA (1) ZA200904152B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95329C2 (ru) * 2006-12-14 2011-07-25 Шеринг-Плау Лтд. Собачий тимусный стромальный лимфопоэтин и его применение
JP5492158B2 (ja) * 2011-08-24 2014-05-14 富士フイルム株式会社 ヒトtsh及び犬tshに対する抗体
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
AR090915A1 (es) 2012-05-04 2014-12-17 Intervet Int Bv Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg
US20160052985A1 (en) * 2013-04-04 2016-02-25 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
PT3031913T (pt) * 2013-08-09 2019-05-31 Astellas Pharma Inc Novo anticorpo anti-receptor de tslp humana
JP6701079B2 (ja) 2013-12-20 2020-05-27 インターベット インターナショナル ベー. フェー. ヒトpd−1に対するイヌ化マウス抗体
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
JP6516925B2 (ja) 2015-09-09 2019-05-22 ノバルティス アーゲー 胸腺間質性リンパ球新生因子(tslp)結合性抗体および抗体を使用する方法
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2017102920A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
CN115028722B (zh) * 2021-03-05 2024-09-03 拜西欧斯(北京)生物技术有限公司 抗tslp抗体及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029581A1 (en) * 1998-11-13 2000-05-25 Immunex Corporation Human tslp dna and polypeptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US6844170B1 (en) 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
AU2396600A (en) 1998-12-30 2000-07-31 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
ES2317917T3 (es) 2000-06-28 2009-05-01 Amgen Inc. Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas.
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
PL1651247T3 (pl) * 2003-07-18 2009-04-30 Schering Corp Leczeni i diagnozowanie nowotworów przy użyciu limfopoetyny zrębu grasicy
EP1786826A4 (en) * 2004-07-28 2008-04-23 Tanox Inc THYMIC STROMAL LYMPHOPOIETINE PROMOTER AND USE THEREOF
SE532251C2 (sv) 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
UA95329C2 (ru) 2006-12-14 2011-07-25 Шеринг-Плау Лтд. Собачий тимусный стромальный лимфопоэтин и его применение

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029581A1 (en) * 1998-11-13 2000-05-25 Immunex Corporation Human tslp dna and polypeptides

Also Published As

Publication number Publication date
US20130183291A1 (en) 2013-07-18
CN101631800A (zh) 2010-01-20
US20080152620A1 (en) 2008-06-26
US8791242B2 (en) 2014-07-29
KR20090097921A (ko) 2009-09-16
AU2007334531B2 (en) 2012-04-12
JP2010512744A (ja) 2010-04-30
ZA200904152B (en) 2011-11-30
UA108064C2 (uk) 2015-03-25
AU2007334531A1 (en) 2008-06-26
RU2617957C2 (ru) 2017-04-28
CN101631800B (zh) 2012-12-05
JP2013048637A (ja) 2013-03-14
US20110033478A1 (en) 2011-02-10
CN102584998A (zh) 2012-07-18
RU2012113162A (ru) 2013-10-20
CA2671865A1 (en) 2008-06-26
WO2008076255A3 (en) 2008-09-18
IL215507A0 (en) 2011-11-30
JP2015107121A (ja) 2015-06-11
CO6210756A2 (es) 2010-10-20
CA2671865C (en) 2017-01-10
US7718772B2 (en) 2010-05-18
JP5707380B2 (ja) 2015-04-30
ES2582655T3 (es) 2016-09-14
RU2457217C2 (ru) 2012-07-27
BRPI0720001A2 (pt) 2013-12-24
EP2104683B1 (en) 2016-05-25
JP6117767B2 (ja) 2017-04-19
NZ578352A (en) 2012-05-25
UA95329C2 (ru) 2011-07-25
US8076456B2 (en) 2011-12-13
EP2104683A2 (en) 2009-09-30
RU2009126617A (ru) 2011-01-20
JP2012090647A (ja) 2012-05-17
UA120027C2 (uk) 2019-09-25
IL199170A (en) 2015-04-30
IN2009CN03372A (https=) 2015-08-07
CN102584998B (zh) 2017-07-04
WO2008076255A2 (en) 2008-06-26
MX2009006470A (es) 2009-06-26

Similar Documents

Publication Publication Date Title
KR101525631B1 (ko) 개 흉선 간질 림포포이에틴 단백질 및 이의 용도
JP6022563B2 (ja) インターロイキン−31モノクローナル抗体
CN112135628B (zh) 抗白介素31的肽疫苗
KR20180124584A (ko) 재조합 n 단백질에 대한 단클론항체를 이용한 아까바네바이러스 블러킹 효소결합면역측정법
JP7126658B2 (ja) 感染性疾患または炎症性疾患の予防および/または治療剤
WO2016005545A1 (en) Substances and methods for the use in prevention and/or treatment in huntington's disease
US7982007B2 (en) Cynomolgus toll-like receptor 3
RU2786441C2 (ru) Пептидные вакцины против интерлейкина-31
JP4829961B2 (ja) プロスタシン部分ペプチド及び抗プロスタシン抗体
JPWO2009116491A1 (ja) ヒトインターフェロンαサブタイプα8及びその変異蛋白質を特異的に認識するモノクローナル抗体
WO2013164435A2 (en) CANINE THYMIC STROMAL LYMPHOPOIETIN PROTEIN FUSION PROTEIN WITH THE Fc REGION OF IgG

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11